Lakewood-Amedex Biotherapeutics Inc. (LABT)

LABT Balance Sheet

Financials in millions usd. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2024	Dec 31, 2023
Cash & Equivalents	0.66	0.68	2.53
Short-Term Investments	-	-	3.86
Cash & Cash Equivalents	0.66	0.68	6.39
Cash Growth	-	-89.34%	-
Other Current Assets	0.12	0.09	0.09
Total Current Assets	0.78	0.77	6.48
Property, Plant & Equipment	-	0.01	0.02
Goodwill and Intangibles	-	0.27	0.39
Other Long-Term Assets	-	0.01	0.01
Total Long-Term Assets	-	0.3	0.41
Total Assets	-	1.07	6.89
Accounts Payable	-	0.17	0.5
Current Debt	-	0.11	0.31
Other Current Liabilities	2.18	0.22	1.26
Total Current Liabilities	2.18	0.5	2.06
Long-Term Debt	-	0.16	0.27
Total Long-Term Liabilities	-	0.16	0.27
Total Liabilities	-	0.66	2.34
Total Debt	1.69	0.27	0.58
Debt Growth	-	-52.86%	-
Retained Earnings	-	-49.5	-44.65
Shareholders' Equity	-1.27	0.41	4.56
Net Cash (Debt)	-1.03	0.41	5.81
Net Cash (Debt) Growth	-	-92.97%	-
Working Capital	-1.4	0.27	4.42

Source: IPO financials are sourced from S-1 and S-1/A filings submitted to the Securities and Exchange Commission (SEC).